Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline ...

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, ...

Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...